Myth: Gender Re-Assignment Surgeries are Being Performed on Minor Children
Claims that gender-affirming care for transgender youth is experimental, harmful, or primarily surgical are contradicted by decades of clinical evidence and the consensus of every major American medical organization. The research consistently shows that access to appropriate care reduces depression, anxiety, and suicide risk in transgender young people.
“"Gender-affirming care for minors is experimental, dangerous, and primarily involves irreversible surgeries — and kids are being permanently harmed by an unproven medical fad driven by ideology rather than science."”
Gender-affirming care is supported by the American Academy of Pediatrics, American Medical Association, American Psychological Association, Endocrine Society, and every other major U.S. medical body. For most youth it means counseling and social steps. Puberty blockers are reversible medications used safely for decades. Surgery on minors is exceedingly rare. Multiple peer-reviewed studies in top medical journals show that access to gender-affirming care significantly reduces suicide risk and improves mental health.
The claim that gender-affirming care is 'experimental' ignores more than 40 years of clinical practice and international medical consensus. The World Professional Association for Transgender Health (WPATH) has published Standards of Care since 1979, now in their eighth edition, establishing evidence-based protocols for treatment. The Endocrine Society has issued clinical practice guidelines on hormone therapy since 2009. The American Academy of Pediatrics, representing over 67,000 pediatricians, formally adopted a gender-affirming care policy in 2018. These are not fringe positions — they represent the accumulated clinical judgment of the institutions that train and credential American physicians.
Puberty blockers (GnRH agonists) are among the most deliberately mischaracterized treatments in current political debate. These medications have been prescribed to cisgender children since the 1980s to treat precocious puberty — a condition where children enter puberty far too early. Their safety profile is well-established over decades of use. When administered to transgender adolescents, they temporarily pause the hormonal changes of puberty, giving young people and their families more time to evaluate options. Multiple studies confirm that the developmental effects are reversible: when puberty blockers are stopped, puberty resumes. They do not cause permanent changes to the body.
Surgical procedures for transgender minors are exceedingly rare and are subject to strict clinical gatekeeping. Researchers analyzing a national pediatric surgical database found only 108 transgender minors who received any gender-affirming surgery across the entire United States over a four-year period — approximately 0.04% of transgender youth nationwide. About 95% of those were chest surgeries, not genital procedures. WPATH's Standards of Care Version 8 recommend that genital surgeries generally not be performed until adulthood. For the overwhelming majority of transgender youth, gender-affirming care means therapy, counseling, family support, and social transition steps such as using a different name and pronouns — not any medical or surgical procedure.
The mental health evidence for gender-affirming care is robust and published in the most rigorous peer-reviewed journals in medicine. Studies in JAMA Pediatrics, Pediatrics, and the New England Journal of Medicine have found that gender-affirming care is associated with significant reductions in depression, anxiety, and suicidal ideation among transgender youth. The 2022 Trevor Project National Survey on LGBTQ Youth Mental Health, which surveyed over 33,000 LGBTQ young people ages 13 to 24, found that transgender and nonbinary youth who reported receiving gender-affirming medical care in the past year had 40% lower odds of having attempted suicide in that same year compared to those who did not receive such care. This is a large, clinically meaningful effect.
Critics of gender-affirming care frequently cite 'detransition' rates to suggest the treatments are harmful and that many people regret them. This framing conflates two very different phenomena. When researchers examine people who stopped treatment or changed their gender identity, studies consistently find that the most common reasons are social pressures — family rejection, discrimination, financial barriers, or social hostility — not medical regret about the care itself. Studies that carefully measure actual medical regret, meaning a person wishes they had not transitioned at all, find rates of 1% to 5%. The highest-quality long-term studies, including a 2021 study published in JAMA Pediatrics following patients who received puberty blockers, found that none of the participants expressed regret about having received treatment.
The American Academy of Pediatrics, American Medical Association, American Psychological Association, and Endocrine Society all support evidence-based gender-affirming care for transgender youth.
Puberty blockers (GnRH agonists) are reversible medications that have been used safely for decades — first approved to treat precocious puberty in cisgender children in the 1980s.
The 2022 Trevor Project survey of over 33,000 LGBTQ youth found that those who received gender-affirming care had 40% lower odds of a suicide attempt in the past year.
Only 108 transgender minors received any gender-affirming surgery in the entire U.S. over a 4-year study period — about 0.04% of transgender youth — with genital procedures representing a tiny fraction of those cases.
Studies in JAMA Pediatrics, Pediatrics, and the New England Journal of Medicine document significant reductions in depression, anxiety, and suicidal ideation among youth who receive gender-affirming care.
Actual medical regret rates in long-term studies are 1–5%; the majority of people who stop treatment do so because of family rejection or social pressure, not because they regret the care itself.
Sources
The AAP's foundational policy statement on care for transgender and gender-diverse children, outlining a gender-affirming model that emphasizes individualized counseling, family support, and social transition — and supports medical intervention only where clinically indicated following evaluation.
The largest survey of LGBTQ youth mental health in the United States, covering over 33,000 respondents ages 13–24. Found that transgender and nonbinary youth who received gender-affirming medical care had 40% lower odds of a suicide attempt in the past year, and that access to affirming adults and spaces dramatically reduced suicide risk.
A 2021 study in JAMA Pediatrics tracking youth who received puberty blockers found that access to pubertal suppression was associated with lower odds of lifetime suicidal ideation. No participants in the study expressed regret about having received treatment.
The Endocrine Society's comprehensive clinical guidelines on hormone therapy and puberty suppression for transgender individuals, first published in 2009 and updated in 2017, representing the consensus of endocrinologists on evidence-based treatment protocols.
The international clinical standard for transgender health care, now in its eighth edition, providing evidence-based guidelines developed since 1979. Version 8 recommends genital surgery generally be reserved for adults and establishes detailed clinical criteria for any consideration of surgical procedures in minors.
A 2023 NEJM study following 315 transgender and nonbinary youth ages 12–20 over two years found that gender-affirming medical care was associated with improved appearance congruence, life satisfaction, and positive affect, along with lower rates of depression and anxiety.